There are currently 3 active clinical trials seeking participants for Renal Failure research studies. The states with the highest number of trials for Renal Failure participants are California, England, New York and Florida.
Prevent Cardiac Surgery Associated AKI Trial
Recruiting
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/29/2024
Locations: George Washington University Hospital, Washington, District of Columbia
Conditions: Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: AKDHC Marana Surgery Center, Marana, Arizona +9 locations
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Recruiting
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Renal Failure